Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지
DOI QR코드

DOI QR Code

Intravenous levetiracetam versus phenobarbital in children with status epilepticus or acute repetitive seizures

  • Lee, Yun-Jeong (Department of Pediatrics, Asan Medical Center Children's Hospital) ;
  • Yum, Mi-Sun (Department of Pediatrics, Asan Medical Center Children's Hospital) ;
  • Kim, Eun-Hee (Department of Pediatrics, Asan Medical Center Children's Hospital) ;
  • Ko, Tae-Sung (Department of Pediatrics, Asan Medical Center Children's Hospital)
  • 투고 : 2015.04.01
  • 심사 : 2015.07.15
  • 발행 : 2016.01.10
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: This study compared the efficacy and tolerability of intravenous (i.v.) phenobarbital (PHB) and i.v. levetiracetam (LEV) in children with status epilepticus (SE) or acute repetitive seizure (ARS). Methods: The medical records of children (age range, 1 month to 15 years) treated with i.v. PHB or LEV for SE or ARS at our single tertiary center were retrospectively reviewed. Seizure termination was defined as seizure cessation within 30 minutes of infusion completion and no recurrence within 24 hours. Information on the demographic variables, electroencephalography and magnetic resonance imaging findings, previous antiepileptic medications, and adverse events after drug infusion was obtained. Results: The records of 88 patients with SE or ARS (median age, 18 months; 50 treated with PHB and 38 with LEV) were reviewed. The median initial dose of i.v. PHB was 20 mg/kg (range, 10-20 mg/kg) and that of i.v. LEV was 30 mg/kg (range, 20-30 mg/kg). Seizure termination occurred in 57.9% of patients treated with i.v. LEV (22 of 38) and 74.0% treated with i.v. PHB (37 of 50) (P=0.111). The factor associated with seizure termination was the type of event (SE vs. ARS) in each group. Adverse effects were reported in 13.2% of patients treated with i.v. LEV (5 of 38; n=4, aggressive behavior and n=1, vomiting), and 28.0% of patients treated with i.v. PHB (14 of 50). Conclusion: Intravenous LEV was efficacious and safe in children with ARS or SE. Further evaluation is needed to determine the most effective and best-tolerated loading dose of i.v. LEV.

키워드

참고문헌

  1. Silbergleit R; National Institutes of Health/National Institute of Neurological Diseases and Stroke Neurological Emergencies Treatment Trials Investigators. Response to Food and Drug Administration draft guidance statement on research into the treatment of life-threatening emergency conditions using exception from informed consent: testimony of the neurological emergencies treatment trials. Acad Emerg Med 2007;14:e63-8. https://doi.org/10.1197/j.aem.2006.12.004
  2. Treiman DM, Meyers PD, Walton NY, Collins JF, Colling C, Rowan AJ, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 1998;339:792-8. https://doi.org/10.1056/NEJM199809173391202
  3. Appleton R, Sweeney A, Choonara I, Robson J, Molyneux E. Lorazepam versus diazepam in the acute treatment of epileptic seizures and status epilepticus. Dev Med Child Neurol 1995;37:682-8.
  4. Eue S, Grumbt M, Muller M, Schulze A. Two years of experience in the treatment of status epilepticus with intravenous levetiracetam. Epilepsy Behav 2009;15:467-9. https://doi.org/10.1016/j.yebeh.2009.05.020
  5. Aiguabella M, Falip M, Villanueva V, de la Pena P, Molins A, Garcia-Morales I, et al. Efficacy of intravenous levetiracetam as an add-on treatment in status epilepticus: a multicentric observational study. Seizure 2011;20:60-4. https://doi.org/10.1016/j.seizure.2010.10.009
  6. Berning S, Boesebeck F, van Baalen A, Kellinghaus C. Intravenous levetiracetam as treatment for status epilepticus. J Neurol 2009; 256:1634-42. https://doi.org/10.1007/s00415-009-5166-7
  7. Moddel G, Bunten S, Dobis C, Kovac S, Dogan M, Fischera M, et al. Intravenous levetiracetam: a new treatment alternative for refractory status epilepticus. J Neurol Neurosurg Psychiatry 2009; 80:689-92. https://doi.org/10.1136/jnnp.2008.145458
  8. Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 2004;43:707-24. https://doi.org/10.2165/00003088-200443110-00002
  9. Ramael S, Daoust A, Otoul C, Toublanc N, Troenaru M, Lu ZS, et al. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia 2006; 47:1128-35. https://doi.org/10.1111/j.1528-1167.2006.00586.x
  10. Gibbs JE, Walker MC, Cock HR. Levetiracetam: antiepileptic properties and protective effects on mitochondrial dysfunction in experimental status epilepticus. Epilepsia 2006;47:469-78. https://doi.org/10.1111/j.1528-1167.2006.00454.x
  11. Lowenstein DH, Bleck T, Macdonald RL. It's time to revise the definition of status epilepticus. Epilepsia 1999;40:120-2. https://doi.org/10.1111/j.1528-1157.1999.tb02000.x
  12. McTague A, Kneen R, Kumar R, Spinty S, Appleton R. Intravenous levetiracetam in acute repetitive seizures and status epilepticus in children: experience from a children's hospital. Seizure 2012; 21:529-34. https://doi.org/10.1016/j.seizure.2012.05.010
  13. Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010;51: 676-85. https://doi.org/10.1111/j.1528-1167.2010.02522.x
  14. Goraya JS, Khurana DS, Valencia I, Melvin JJ, Cruz M, Legido A, et al. Intravenous levetiracetam in children with epilepsy. Pediatr Neurol 2008;38:177-80. https://doi.org/10.1016/j.pediatrneurol.2007.11.003
  15. Kirmani BF, Crisp ED, Kayani S, Rajab H. Role of intravenous levetiracetam in acute seizure management of children. Pediatr Neurol 2009;41:37-9. https://doi.org/10.1016/j.pediatrneurol.2009.02.016
  16. Reiter PD, Huff AD, Knupp KG, Valuck RJ. Intravenous levetiracetam in the management of acute seizures in children. Pediatr Neurol 2010;43:117-21. https://doi.org/10.1016/j.pediatrneurol.2010.03.017
  17. Kim JS, Lee JH, Ryu HW, Lim BC, Hwang H, Chae JH, et al. Effectiveness of intravenous levetiracetam as an adjunctive treatment in pediatric refractory status epilepticus. Pediatr Emerg Care 2014; 30:525-8. https://doi.org/10.1097/PEC.0000000000000183
  18. Isguder R, Guzel O, Agin H, Yilmaz U, Akarcan SE, Celik T, et al. Efficacy and safety of IV levetiracetam in children with acute repetitive seizures. Pediatr Neurol 2014;51:688-95. https://doi.org/10.1016/j.pediatrneurol.2014.07.021
  19. Abend NS, Monk HM, Licht DJ, Dlugos DJ. Intravenous levetiracetam in critically ill children with status epilepticus or acute repetitive seizures. Pediatr Crit Care Med 2009;10:505-10. https://doi.org/10.1097/PCC.0b013e3181a0e1cf
  20. Yasiry Z, Shorvon SD. The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: a meta-analysis of published studies. Seizure 2014;23:167-74. https://doi.org/10.1016/j.seizure.2013.12.007
  21. Ng YT, Hastriter EV, Cardenas JF, Khoury EM, Chapman KE. Intravenous levetiracetam in children with seizures: a prospective safety study. J Child Neurol 2010;25:551-5. https://doi.org/10.1177/0883073809348795

피인용 문헌

  1. Efficacy and Safety of Intravenous Levetiracetam Therapy for Repetitive Seizures and Status Epilepticus in Children vol.36, pp.3, 2019, https://doi.org/10.3805/jjes.36.630
  2. Meta-analysis and cost-effectiveness of second-line antiepileptic drugs for status epilepticus vol.92, pp.20, 2016, https://doi.org/10.1212/wnl.0000000000007503
  3. Status Epilepticus-Work-Up and Management in Children vol.40, pp.6, 2016, https://doi.org/10.1055/s-0040-1719076
  4. European Resuscitation Council Guidelines 2021: Paediatric Life Support vol.161, pp.None, 2016, https://doi.org/10.1016/j.resuscitation.2021.02.015
  5. Lebensrettende Maßnahmen bei Kindern (Paediatric Life Support, PLS) : Leitlinien des European Resuscitation Council 2021 vol.24, pp.4, 2016, https://doi.org/10.1007/s10049-021-00887-9